ShangPharma, the Shanghai-based CRO, formally announced that it had received a "more than" $30 million investment from private equity firm TPG, an event we reported earlier. Reuters used the news release to assert that ShangPharma was contemplating an IPO that will be completed in the next year. Reuters did not identify any sources for that part of the story, and there was no official confirmation. More details...

Stock Symbols: (NYSE: WX) (NYSE: LLY)